XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer | Zendy

Jifeng Feng | Zendy; Xinchen Sun | Zendy; Ning Sun | Zendy; Shukui Qin | Zendy; Fan Li | Zendy; Hongyan Cheng | Zendy; Baoan Chen | Zendy; Yuandong Cao | Zendy; Jun Ma | Zendy; Lü Cheng | Zendy; Zuhong Lu | Zendy; Jiazhong Ji | Zendy; Zhou Yingfeng | Zendy

Open Access

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer

Author(s) -

Jifeng Feng,

Xinchen Sun,

Ning Sun,

Shukui Qin,

Fan Li,

Hongyan Cheng,

Baoan Chen,

Yuandong Cao,

Jun Ma,

Lü Cheng,

Zuhong Lu,

Jiazhong Ji,

Zhou Yingfeng

Publication year - 2009

Publication title -

acta biochimica et biophysica sinica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 57

eISSN - 1745-7270

pISSN - 1672-9145

DOI - 10.1093/abbs/gmp027

Subject(s) - xeroderma pigmentosum , nucleotide excision repair , dna repair , ercc1 , chemotherapy , cancer research , lung cancer , biology , dna damage , dna , gene , oncology , medicine , genetics

DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research